Perivascular adipokine signaling in abdominal aortic aneurysm: cardiometabolic drivers of vascular remodeling and translational opportunities.

Authors

Xinyi Zhang, Hanxun He, Hang He, Yujin Zhang, Yuxiao Zhang, Yufan Zhou, Xiaofan Huang, Jiaqi Huang, Ping Ye, Jiahong Xia

Published in

Cardiovascular diabetology. Volume 25. Issue 1. Jun 13, 2026. Epub Jun 13, 2026.

Abstract

Abdominal aortic aneurysm (AAA) represents a significant vascular pathology characterized by high mortality rates and a paucity of effective pharmacological interventions. Recent research underscores the role of perivascular adipose tissue derived adipokines in establishing a direct connection between obesity and the pathogenesis of AAA. These adipokines exert influence on aneurysmal remodeling by modulating the functions of vascular cells, particularly in relation to inflammation and extracellular matrix degradation. They can be categorized into two broad classes: deleterious (pro-aneurysmal) and protective (anti-aneurysmal). Deleterious adipokines exacerbate AAA through the promotion of inflammation, the weakening of the vascular wall, and the stimulation of aberrant vascular growth. In contrast, protective adipokines contribute to the attenuation of AAA progression via antioxidative, anti-inflammatory, and vascular homeostatic mechanisms. Recent evidence indicates that restoring adipokine balance may serve as a promising therapeutic approach for AAA. Although the majority of studies are still in the preclinical stage, the repurposing of metabolic drugs such as GLP-1 receptor agonists, metformin, and PPAR agonists has shown potential in rebalancing adipokine profiles, reducing inflammation, and promoting vascular repair. Additionally, novel agents targeting adipokine receptors, including adiponectin agonists, chemerin antagonists, and FABP4 inhibitors, have demonstrated preliminary efficacy in modulating adipokine signaling and mitigating vascular inflammation. This review synthesizes the mechanistic roles of adipokines in AAA, with a focus on therapeutic opportunities targeting adipokine driven pathways, and outlines a framework for future translational and clinical research aimed at adipokine-based management of AAA.

PMID:
42288888
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.